https://scholars.lib.ntu.edu.tw/handle/123456789/586131
標題: | Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry | 作者: | Drilon A. Duruisseaux M. Han J.-Y. Ito M. Falcon C. Yang S.-R. Murciano-Goroff Y.R. Chen H. Okada M. Molina M.A. Wislez M. Brun P. Dupont C. Branden E. Rossi G. Schrock A. Ali S. Gounant V. Magne F. Blum T.G. Schram A.M. Monnet I. JIN-YUAN SHIH Sabari J. Pérol M. Zhu V.W. Nagasaka M. Doebele R. Camidge D.R. Arcila M. Ou S.-H.I. Moro-Sibilot D. Rosell R. Muscarella L.A. Liu S.V. Cadranel J. |
公開日期: | 2021 | 出版社: | NLM (Medline) | 卷: | 39 | 期: | 25 | 起(迄)頁: | 2791-2802 | 來源出版物: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 摘要: | PURPOSE: Although NRG1 fusions are oncogenic drivers across multiple tumor types including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 registry was thus established to characterize NRG1 fusion-positive lung cancer |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108078188&doi=10.1200%2fJCO.20.03307&partnerID=40&md5=6ea7d0ffbf8c8dabcadfb57377eb3928 https://scholars.lib.ntu.edu.tw/handle/123456789/586131 |
ISSN: | 1527-7755 | DOI: | 10.1200/JCO.20.03307 | SDG/關鍵字: | antineoplastic agent; neu differentiation factor; NRG1 protein, human; oncoprotein; tumor marker; adult; aged; Asia; clinical trial; Europe; female; follow up; genetics; human; immunology; immunotherapy; lung tumor; male; middle aged; mortality; multicent |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。